Alpha 2.0
Login Register
» Authors » I Tinhofer

I Tinhofer

Explore the profile of I Tinhofer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 610
Followers 0
Related Specialties
Oncology
Cell Biology
Hematology
Top 10 Co-Authors
R Greil
V Budach
A Egle
R Konschak
C Stromberger
W Weichert
K Maly
T Henn
D Zips
I Marschitz
Published In
Ann Oncol
Eur J Cancer
Blood
HNO
J Biol Chem
Affiliations
Soon will be listed here.
Recent Articles
1.
Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma
Martin D, Rodel F, Hehlgans S, Looso M, Ziegler P, Fleischmann M, et al.
NPJ Precis Oncol . 2024 Apr; 8(1):93. PMID: 38653773
Anal squamous cell carcinoma (ASCC) is associated with immunosuppression and infection with human papillomavirus (HPV). Response to standard chemoradiotherapy (CRT) varies considerably. A comprehensive molecular characterization of CRT resistance is...
2.
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)
Martin D, Schreckenbach T, Ziegler P, Filmann N, Kalinauskaite G, Tinhofer I, et al.
Radiother Oncol . 2022 Jan; 167:233-238. PMID: 34999135
Background And Purpose: Prognosis after chemoradiotherapy (CRT) for anal squamous cell carcinoma (ASCC) shows marked differences among patients according to TNM subgroups, however individualized risk assessment tools to better stratify...
3.
Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group
Eder T, Hess A, Konschak R, Stromberger C, Johrens K, Fleischer V, et al.
Eur J Cancer . 2019 Jun; 116:67-76. PMID: 31173964
Background: Tumour mutational burden (TMB) estimated from whole exome sequencing or comprehensive gene panels has previously been established as predictive factor of response to immune checkpoint inhibitors (ICIs). Its predictive...
4.
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach
Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, et al.
Ann Oncol . 2018 Oct; 29(12):2313-2327. PMID: 30307465
The molecular landscape of squamous cell carcinoma of the head and the neck (SCCHN) has been characterized and actionable or targetable genomic alterations have been identified. However, targeted therapies have...
5.
Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation
Tinhofer I, Stenzinger A, Eder T, Konschak R, Niehr F, Endris V, et al.
Ann Oncol . 2016 Sep; 27(12):2262-2268. PMID: 27681865
Background: Based on epidemiological (HPV status, smoking habits) and clinical risk factors (T/N stage), three subgroups of patients suffering from locally advanced oropharyngeal carcinoma with significantly different outcome after concurrent...
6.
Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation
Tinhofer I, Budach V, Saki M, Konschak R, Niehr F, Johrens K, et al.
Eur J Cancer . 2016 Feb; 57:78-86. PMID: 26896955
Background: Despite clear differences in clinical presentation and outcome, squamous cell carcinomas of the head and neck (SCCHN) arising from human papilloma virus (HPV) infection or heavy tobacco/alcohol consumption are...
7.
[The role of microRNAs in head and neck squamous cell carcinoma : Biomarkers for prognosis, therapy selection, and novel therapeutics]
Hess A, Weichert W, Budach V, Tinhofer I
HNO . 2016 Jan; 64(5):296-302. PMID: 26746640
Despite recent advances in radiochemotherapy, treatment of locally advanced head and neck squamous cell carcinoma is still challenging, and survival rates have improved only slightly. This is due to the...
8.
[HPV-associated head and neck cancer : mutational signature and genomic aberrations]
Wagner S, Wurdemann N, Hubbers C, Reuschenbach M, Prigge E, Wichmann G, et al.
HNO . 2015 Oct; 63(11):758-67. PMID: 26507715
A significantly increasing proportion of oropharyngeal head and neck carcinomas (OSCC) in North America and Europe are associated with human papillomavirus (HPV) infections. HPV-related OSCC is regarded as a distinct...
9.
Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence
Tinhofer I, Johrens K, Keilholz U, Kaufmann A, Lehmann A, Weichert W, et al.
Eur J Cancer . 2015 Jan; 51(4):514-521. PMID: 25623438
Background: Increases in incidence of oropharyngeal squamous cell carcinoma (OPSCC) in countries with falling tobacco use have been attributed to a growing role of human papilloma virus (HPV) in the...
10.
Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck
Tinhofer I, Konschak R, Stromberger C, Raguse J, Dreyer J, Johrens K, et al.
Ann Oncol . 2014 Jul; 25(10):2042-2047. PMID: 25057171
Background: The prognostic role of persistence of circulating tumor cells (CTC) after upfront tumor surgery for outcome of adjuvant (chemo)radiation in locally advanced squamous cell carcinoma of the head and...